Values as of: 2024-10-01
COMMON STOCK | REIT - Healthcare Facilities |
Last Closing
USD 0.524Change
0.00 (0.00)%Market Cap
USD 1.70BVolume
100.00Analyst Target
N/AVerdict
Verdict
Assura plc is a national healthcare premises specialist and UK REIT based in Altrincham, UK - caring for more than 600 primary healthcare buildings, from which over six million patients are served. A constituent of the FTSE 250 and the EPRA indices, as at 30 September 2023, Assura's portfolio was valued at £2.7 billion. At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026. Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.
Company Website : https://www.assuraplc.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| CWSRF | Chartwell Retirement Residence.. |
N/A |
USD 3.10B |
| PHPRF | Primary Health Properties PLC |
N/A |
USD 1.59B |
| SILA | Sila Realty Trust, Inc. |
+0.24 (+0.95%) |
USD 1.38B |
| HLTC | HealthCare Inc |
N/A |
USD 0.34B |
| NWHUF | Northwest Healthcare Propertie.. |
-0.04 (-0.86%) |
N/A |
| PRKWF | Parkway Life Real Estate Inves.. |
N/A |
N/A |
N/A
| Market Performance vs. Industry/Classification (REIT - Healthcare Facilities) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -19.38% | 17% | F | 33% | F | ||
| Dividend Return | 18.66% | 100% | F | 94% | A | ||
| Total Return | -0.72% | 17% | F | 48% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 2.14% | 33% | F | 53% | F | ||
| Dividend Return | 25.65% | 100% | F | 95% | A | ||
| Total Return | 27.80% | 83% | B | 71% | C- | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -12.74% | N/A | N/A | 19% | F | ||
| Dividend Return | -9.05% | N/A | N/A | 22% | F | ||
| Total Return | 3.69% | N/A | N/A | 62% | D | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 14.35% | N/A | N/A | 93% | A | ||
| Risk Adjusted Return | -63.03% | N/A | N/A | 12% | F | ||
| Market Capitalization | 1.70B | 80% | B- | 77% | C+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
